Jay Sosenko

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi request reprint Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study
    Jay M Sosenko
    University of Miami School of Medicine, Miami, Florida, USA
    Diabetes Care 25:1078-84. 2002
  2. pmc Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Tihamer Orban
    Joslin Diabetes Center, Boston, Massachusetts, USA
    Diabetes Care 32:2269-74. 2009
  3. pmc Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes
    Jay M Sosenko
    Corresponding author Jay M Sosenko
    Diabetes Care 37:979-84. 2014
  4. pmc The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 36:2615-20. 2013
  5. pmc The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Diabetes Care 35:1552-5. 2012
  6. pmc A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants
    Jay M Sosenko
    ivision of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 34:2435-7. 2011
  7. pmc Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1)
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes 59:2386-9. 2010
  8. pmc A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Pediatr Diabetes 12:85-90. 2011
  9. pmc Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 33:620-5. 2010
  10. ncbi request reprint The prevalence of diabetic neuropathy according to ethnicity
    Jay M Sosenko
    Diabetes Research Institute, Miami, FL 33136, USA
    Curr Diab Rep 9:435-9. 2009

Detail Information

Publications23

  1. ncbi request reprint Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study
    Jay M Sosenko
    University of Miami School of Medicine, Miami, Florida, USA
    Diabetes Care 25:1078-84. 2002
    ..We have used a prospective cohort study to examine this...
  2. pmc Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Tihamer Orban
    Joslin Diabetes Center, Boston, Massachusetts, USA
    Diabetes Care 32:2269-74. 2009
    ..Thus, we studied the extent to which specific autoantibodies are predictive of type 1 diabetes...
  3. pmc Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes
    Jay M Sosenko
    Corresponding author Jay M Sosenko
    Diabetes Care 37:979-84. 2014
    ..The 7.00 DPTRS threshold characterizes risk more consistently between populations and has greater reliability than dysglycemia. ..
  4. pmc The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 36:2615-20. 2013
    ..We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D)...
  5. pmc The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Diabetes Care 35:1552-5. 2012
    ..We assessed the utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for identifying individuals who are highly likely to progress to type 1 diabetes (T1D) within 2 years...
  6. pmc A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants
    Jay M Sosenko
    ivision of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 34:2435-7. 2011
    ..We examined changes in GAD65 and ICA-512 autoantibodies (GADA and IA-2A) during progression to type 1 diabetes (T1D)...
  7. pmc Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1)
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes 59:2386-9. 2010
    ..We characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied whether those fluctuations are related to the early C-peptide response to oral glucose...
  8. pmc A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, FL, USA
    Pediatr Diabetes 12:85-90. 2011
    ..We assessed whether differing autoantibody screening criteria for type 1 diabetes (T1D) prevention trials result in different baseline metabolic profiles of those who screen positive...
  9. pmc Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 33:620-5. 2010
    ..001); peak C-peptide levels were less predictive (P < 0.05). CONCLUSIONS A decreased early C-peptide response to oral glucose and an increased later response occur at least 2 years before the diagnosis of type 1 diabetes...
  10. ncbi request reprint The prevalence of diabetic neuropathy according to ethnicity
    Jay M Sosenko
    Diabetes Research Institute, Miami, FL 33136, USA
    Curr Diab Rep 9:435-9. 2009
    ..However, this trend is not always consistent and there is no clear explanation for it...
  11. pmc Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study
    Jay M Sosenko
    University of Miami, Miami, FL, USA
    Diabetes Care 34:1785-7. 2011
    ..We assessed the accuracy of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), developed from the Diabetes Prevention Trial-Type 1 (DPT-1), in the TrialNet Natural History Study (TNNHS)...
  12. pmc Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 32:1603-7. 2009
    ..We studied the incidence of dysglycemia and its prediction of the development of type 1 diabetes in islet cell autoantibody (ICA)-positive individuals. In addition, we assessed whether dysglycemia was sustained...
  13. pmc Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, Miami, Florida, USA
    Diabetes Care 31:2188-92. 2008
    ..We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial-Type 1 (DPT-1) participants...
  14. ncbi request reprint The epidemiology of neuropathic foot ulcers in individuals with diabetes
    Jay Sosenko
    University of Miami, School of Medicine, P O Box 016960 R 53, Miami, FL 33101, USA
    Curr Diab Rep 2:477-81. 2002
    ....
  15. ncbi request reprint Sensory function and albumin excretion according to diagnostic criteria for diabetes
    Jay M Sosenko
    Department of Medicine, University of Miami School of Medicine, Miami, FL 33101, USA
    Diabetes Care 27:1716-20. 2004
    ..The purpose of this study was to examine sensory function and albumin excretion according to categories of glucose tolerance in individuals undergoing screening for diabetes...
  16. ncbi request reprint Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 29:643-9. 2006
    ..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis...
  17. ncbi request reprint Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
    ....
  18. ncbi request reprint A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 31:528-33. 2008
    ..The accurate prediction of type 1 diabetes is essential for appropriately identifying prevention trial participants. Thus, we have developed a risk score for the prediction of type 1 diabetes...
  19. ncbi request reprint Unusually difficult challenges in human-subjects research
    Arturo Brito
    P O Box 016960 M 820, Miami, FL, USA
    Prof Ethics 11:39-43. 2003
  20. ncbi request reprint Diabetic neuropathies: a statement by the American Diabetes Association
    Andrew J M Boulton
    Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, U K
    Diabetes Care 28:956-62. 2005
  21. ncbi request reprint Diabetic somatic neuropathies
    Andrew J M Boulton
    Division of Endocrinology, University of Miami School of Medicine, P O Box 016960 D 110, Miami, Florida, USA
    Diabetes Care 27:1458-86. 2004
  22. ncbi request reprint Incidence of lower-extremity amputation in American Indians: the Strong Heart Study
    Helaine E Resnick
    Department of Epidemiology and Statistics, MedStar Research Institute, 6495 New Hampshire Ave, Suite 201, Hyattsville, MD 20783, USA
    Diabetes Care 27:1885-91. 2004
    ..To define incidence and predictors of nontraumatic lower-extremity amputation (LEA) in a diverse cohort of American Indians with diabetes...